While it significantly reduces appetite, full suppression may not be achievable for everyone
Wegovy 0.5 mg (semaglutide) is the second step in the clinically approved titration schedule for GLP-1based weight loss. After completing the 0.25 mg starter dose, this intermediate strength helps the body continue adapting while enhancing appetite suppression, supporting metabolic function and sustainable fat loss
Ozempic is the most popular brand-name semaglutide medication, available as an injectable (subcutaneous) formulation, to improve glycemic control in adults with type 2 diabetes, reduce the risk of cardiovascular events (heart attack, heart failure, and stroke), and prevent worsening kidney disease or kidney failure
A recent pooled analysis integrating data from these withdrawal trials (n=800) reported a mean absolute weight regain of 9.69 kg after discontinuation of semaglutide or tirzepatide [118], underscoring the chronic and relapsing nature of obesity that necessitates long-term pharmacologic management
There is no universal standard